DOCSLIB.ORG

Information for the User

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information for the User 155 mm 20 mm 135 mm Package leaflet: Information for the User Aronix® 50 mg Film-Coated Tablets STOP TAKING Aronix and seek medical attention IMMEDIATELY if you experience any of the Sildenafil 40 mm following SERIOUS side effects: Read all of this leaflet carefully before you start taking this medicine because it contains important • chest pains: this occurs uncommonly. information for you. If this occurs before, during or after intercourse get Always take this medicine exactly as described in this leaflet or as your pharmacist has told you. in a semi-sitting position and try to relax. • Keep this leaflet. You may need to read it again. Do NOT use nitrates to treat your chest pain • Ask your pharmacist if you need more information or advice. • a persistent and sometimes painful erection • If you get any side effects, talk to your pharmacist or doctor. This includes any possible side effects not listed lasting longer than 4 hours: this occurs rarely in this leaflet. See section 4. • a sudden decrease or loss of vision: this occurs • If you have taken Aronix as directed and were NOT able to get or keep an erection hard enough for rarely satisfactory sex, you should talk to your pharmacist or doctor. • an allergic reaction: this occurs uncommonly. Symptoms include sudden wheeziness, difficulty What is in this leaflet Children and adolescents breathing or dizziness, swelling of the eyelids, 40 mm face, lips or throat 1. What Aronix is and what it is used for This medicine should not be given to children and • serious skin reactions such as Stevens-Johnson 2. What you need to know before you take Aronix adolescents under the age of 18 years. Syndrome (SJS) and Toxic Epidermal Syndrome 3. How to take Aronix (TEN): this occurs rarely. Symptoms may include 4. Possible side effects Other medicines and Aronix Tell your pharmacist or doctor if you are taking, have severe peeling and swelling of the skin, blistering 5. How to store Aronix of the mouth, genitals and around the eyes, fever 6. Contents of the pack and other information recently taken or might take any other medicines. Some medicines may be affected by Aronix or they • seizures or fits: this occurs rarely. may affect how well Aronix will work. 1. What Aronix is and what it is used for Other side effects that have been reported: Nitrate medicines: Do NOT take Aronix if you are Very common (may affect more than 1 in 10 people): Aronix is a treatment for adult men (aged 18 years taking nitrate medicines (such as glyceryl headache. and older) with erectile dysfunction (also known as trinitrate, isosorbide mononitrate, isosorbide impotence). This is when a man cannot get or keep an dinitrate) or nitric oxide donors (such as amyl Common (may affect up to 1 in 10 people): erection hard enough for satisfactory sexual activity. nitrite (“poppers”), nicorandil or sodium 40 mm • nausea, indigestion, stuffy nose, dizziness nitroprusside). • facial flushing, hot flush (symptoms include a Erections depend on many things, including proper These are often used for the relief of chest pain sudden feeling of heat in your upper body) blood flow to the penis. If blood cannot flow (angina pectoris), or heart failure. • colour tinge to vision, blurred vision, visual adequately to the penis, it can cause erectile Using Aronix with any of these medicines may lead to disturbance dysfunction. Erectile dysfunction is a common problem a dangerous fall in blood pressure. and can affect men differently. Some men cannot get Uncommon (may affect up to 1 in 100 people): an erection, other men can get an erection but it may Do not take Aronix if you are taking a medicine called • vomiting, upper abdominal pain, not be hard enough for sex, or they may lose their riociguat (or other medicines of a group called gastro-oesophageal reflux disease (also known as erection before or during sex. guanylate cyclase stimulators), used to treat acid reflux with symptoms including heartburn) Aronix contains the active ingredient sildenafil. pulmonary arterial hypertension (i.e. high blood • skin rash, pain in the arms or legs, nosebleed, It belongs to a group of medicines called pressure in the lungs) and chronic thromboembolic feeling hot, feeling tired phosphodiesterase type 5 (PDE5) inhibitors. pulmonary hypertension (i.e. high blood pressure in • eye irritation, bloodshot eyes/red eyes, eye pain, It works by relaxing the blood vessels in your penis, the lungs due to blood clots). 40 mm seeing flashes of light, visual brightness, light sensitivity, watery eyes allowing blood to flow into your penis when you get In addition, do not take Aronix if you are taking a sexually excited and causing an erection. • pounding heartbeat, rapid heartbeat medicine called ritonavir, for the treatment for HIV • high blood pressure Aronix will only help you to get an erection if you are infection. sexually excited (stimulated). • low blood pressure (symptoms include dizziness, Tell your pharmacist or doctor before using Aronix if fainting, blurred vision, nausea and tiredness) • muscle pain, feeling sleepy, reduced sense of 2. What you need to know before you you are taking: • any other treatment for erectile dysfunction touch, vertigo, ringing in the ears take Aronix • alpha-blockers such as alfuzosin, doxazosin or • dry mouth, blocked or stuffy sinuses, inflammation tamsulosin, which are medicines used to treat of the lining of the nose (symptoms include runny Do not take Aronix if you: urinary problems due to an enlarged prostate nose, sneezing and stuffy nose) • do not have an erection problem, as this medicine (benign prostatic hyperplasia) or occasionally high • presence of blood in urine will not provide any benefit to you blood pressure, as Aronix may not be suitable for 40 mm Rare (may affect up to 1 in 1,000 people): • take any medicines called nitrates or nitric you • fainting, dry nose, swelling of the inside of the oxide donors, (such as glyceryl trinitrate, • medicines that may affect the way Aronix works nose, feeling irritable and sudden decrease or loss isosorbide mononitrate, isosorbide dinitrate for the such as: of hearing relief of chest pain, or heart failure or amyl nitrite - protease inhibitors (saquinavir) to treat HIV • stroke, heart attack, irregular heartbeat, temporary also known as “poppers”, nicorandil or sodium infections decreased blood flow to parts of the brain nitroprusside), as the combination may lead to a - the heartburn treatment cimetidine • feeling of tightening of the throat, numb mouth dangerous fall in blood pressure - medicines to treat fungal infections called • bleeding at the back of the eye, double vision, • are allergic to sildenafil or any of the other itraconazole or ketoconazole, and an antibiotic reduced sharpness of vision, abnormal sensation ingredients of this medicine (listed in section 6) called erythromycin. in the eye, swelling of the eye or eyelid, small • take riociguat or other medicines of a group called Aronix may not be suitable for you. Ask your particles or spots in your vision, seeing halos guanylate cyclase stimulators. This medicine is pharmacist or doctor about a 25 mg tablet which around lights, dilation of the pupil of the eye, used to treat pulmonary arterial hypertension may be more suitable for you. discolouration of the white of the eye (i.e. high blood pressure in the lungs) and chronic 40 mm • penile bleeding, presence of blood in semen. thromboembolic pulmonary hypertension (i.e. high Aronix with food and drink blood pressure in the lungs due to blood clots). Aronix can be taken with or without food. When this Cases of unstable angina (a heart condition) and • take ritonavir for the treatment of HIV infection medicine is taken after a high-fat meal, it may take a sudden death have been reported rarely. Of note, • have been advised by your doctor to avoid sexual little longer to start working. Do not take Aronix with most, but not all, of the men who experienced these activity because of a problem with your heart or grapefruit or grapefruit juice, because this can affect side effects had heart problems before taking this blood vessels, such as a recent heart attack or how the medicine works. medicine. It is not possible to determine whether these stroke (within the last 6 months), unstable angina Drinking excessive alcohol can temporarily reduce events were directly related to this medicine. or severe cardiac failure your ability to get an erection. To get the maximum • have ever had loss of vision because of damage to benefit from your medicine, you are advised not to Reporting of side effects the optic nerve [such as non-arteritic anterior drink large amounts of alcohol before sexual activity. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not ischaemic optic neuropathy (NAION)] or have an Pregnancy, breastfeeding and fertility inherited eye disease (such as retinitis listed in this leaflet. You can also report side effects This medicine should not be used by women. 40 mm pigmentosa) directly via the Yellow Card Scheme website • have low blood pressure (which can cause Driving and using machines www.mhra.gov.uk/yellowcard or search for MHRA symptoms such as tiredness, dizziness, Aronix can cause dizziness and can affect your vision. Yellow Card in the Google Play or Apple App Store. lightheadedness, feeling sick, clammy skin, Do not drive or use machines if you suffer from these By reporting side effects you can help provide more depression, loss of consciousness, or blurry vision) side effects after taking this medicine. information on the safety of this medicine. or high blood pressure that is not controlled • have a severe liver problem Important information about some of the 5.
Load more

Recommended publications
  • Pneumocystis Pneumonia and Disseminated
    1614 BRITISH MEDICAL JOURNAL VOLUmE 286 21 MAY 1983 Br Med J (Clin Res Ed): first published as 10.1136/bmj.286.6378.1614-a on 21 May 1983. Downloaded from Pneumocystis pneumonia and discussions, and Dr B Jameson and Dr D G Fleck for their valuable assistance disseminated toxoplasmosis in a with the pneumocystis and toxoplasma serology. Ammann A, Cowan M, Wara D, et al. Possible transfusion-associated male homosexual acquired immune deficiency syndrome (AIDS)-California. Morbidity and Mortality Weekly Report 1982;31 :652-4. 2 Du Bois RM, Branthwaite MA, Mikhail JR, et al. Primary pneumocystis Within the past two years 788 cases of the apparently new and carinii and cytomegalovirus infections. Lancet 1981 ;ii: 1339. potentially lethal syndrome of acquired immune deficiency have been Oswald GA, Theodossi A, Gazzard BG, et al. Attempted immune stimula- reported in the United States.' Only three cases have been reported in tion in the "gay compromise syndrome." Br MedJ' 1982;285:1082. the United Kingdom.2-4 We report a case in a previously healthy 37 4 Maurice PDL, Smith NP, Pinching AJ. Kaposi's sarcoma with benign course in a homosexual. Lancet 1982;i:571. year old male homosexual who was initially diagnosed and treated for Task force on acquired immune deficiency syndrome, Centers for Disease pneumocystis pneumonia and subsequently died of widespread Control. Update on acquired immune deficiency syndrome (AIDS)- toxoplasmosis. United States. Morbidity and Mortality Weekly Report 1982;31:507-14. (Accepted 4 March 1983) Case report The patient presented with an eight week history of malaise, non-produc- Departments of Microbiology and Medicine, St Thomas's Hospital, tive cough, night sweats, diarrhoea, anorexia, and weight loss.
    [Show full text]
  • ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity
    ATSDR Case Studies in Environmental Medicine Nitrate/Nitrite Toxicity Agency for Toxic Substances and Disease Registry Case Studies in Environmental Medicine (CSEM) Nitrate/Nitrite Toxicity Course: WB2342 CE Original Date: December 5, 2013 CE Expiration Date: December 5, 2015 Key • Nitrate toxicity is a preventable cause of Concepts methemoglobinemia. • Infants younger than 4 months of age are at particular risk of nitrate toxicity from contaminated well water. • The widespread use of nitrate fertilizers increases the risk of well-water contamination in rural areas. About This This educational case study document is one in a series of and Other self-instructional modules designed to increase the primary Case Studies care provider’s knowledge of hazardous substances in the in environment and to promote the adoption of medical Environmen- practices that aid in the evaluation and care of potentially tal Medicine exposed patients. The complete series of Case Studies in Environmental Medicine is located on the ATSDR Web site at URL: http://www.atsdr.cdc.gov/csem/csem.html In addition, the downloadable PDF version of this educational series and other environmental medicine materials provides content in an electronic, printable format. Acknowledgements We gratefully acknowledge the work of the medical writers, editors, and reviewers in producing this educational resource. Contributors to this version of the Case Study in Environmental Medicine are listed below. Please Note: Each content expert for this case study has indicated that there is no conflict of interest that would bias the case study content. CDC/ATSDR Author(s): Kim Gehle MD, MPH CDC/ATSDR Planners: Charlton Coles, Ph.D.; Kimberly Gehle, MD; Sharon L.
    [Show full text]
  • Nitrocompounds, Aliphatic: Physical & Chemical Properties
    Nitrocompounds, Aliphatic: Physical & Chemical Properties, Encyclopaedia of Occupational Health and Safety, Jeanne Mager Stellman, Editor-in-Chief. International Labor Organization, Geneva. 2011 Chemical Name Colour/Form Boiling Point Melting Molecular Solubility in Relative Density Relative Vapour Inflam. Flash Auto CAS-Number (°C) Point (°C) Weight Water (water=1) Vapour Pressure/ Limits Point (ºC) Ignition Density (Kpa) Point (º C) (air=1) AMYL NITRITE yellowish, transparent 99 117.1 sl sol 0.8828 4.0 110-46-3 liquid 1-CHLORO-1-NITRO- 124.5 109.51 insol 1.2837 ETHANE 598-92-5 2-CHLORO-2-NITRO- liquid 133.6 123.55 0.5 ml sol in 1.197 4.3 8.5 mm Hg 57 ° C oc PROPANE 100 ml @ 20 ° C/20 ° @ 25 ° C 594-71-8 @ 20 ° C C 1-CHLORO-1-NITRO- liquid 143 123.54 0.5ml/100 ml 1.209 0.3 5.8 mm Hg 62 oc PROPANE @ 25 ºC 600-25-9 CHLOROPICRIN slightly oily liquid; 112 -69.2 164.4 sol 1.6558 5.7 5.7 mm Hg 76-06-2 colourless; faint yellow @ 0 º C liquid. 1,1-DICHLORO-1-NI- colourless liquid 124 143.9 0.25 ml/100 m 1.4271 5.0 16.0 mm Hg 76 oc TROETHANE l @ 25 ºC 594-72-9 DIETHYLENE GLYCOL liquid 161 -11.6 sl sol 1.377 DINITRATE @ 25 ºC 693-21-0 ETHYLENE GLYCOL yellowish, oily liquid; 197-200 -22.3 152.06 insol 1.4918 5.24 7 Pa 215 cc 114 DINITRATE colourless 628-96-6 ETHYLENE GLYCOL pale yellow, viscous liquid 197-200 -22.3 152.06 sl sol 1.4978 218 DINITRATE mixed with NITROGLYCERIN (1:1) 53569-64-5 ETHYL NITRATE colourless liquid 87.2 ° C at 762 94.6 ° C 91.07 1.3 g in 100 1.1084 at 20 ° 3.1 lower, 4.0% 10 625-58-1 mm Hg ml C/4 ° C by vol @ 55 ° C ETHYL
    [Show full text]
  • The History of Glyceryl Trinitrate As a Prescription Drug
    patches for transdermal delivery and in tablet form. It ARTICLE may also be injected. Th e history of glyceryl trinitrate as a prescription drug Anthony Butler Abstract A number of prescribed drugs possessing a nitro group (-NO2) are vasodilators and are used to relieve the symptoms of angina pectoris. Th e most widely pre- scribed drug in this group is glyceryl trinitrate (GTN). It was fi rst synthesized by an Italian chemist, Ascanio Sobrero, in 1847. Its clinical use was pioneered by phy- sicians including William Murrell and Sir Th omas Lauder Brunton, and it is now an established remedy for the condition. Its mode of action in vivo was a com- plete mystery until the discovery in the 1980s of nitric oxide (NO) as the naturally occurring messenger mol- ecule that triggers the process of vasodilation. However, exactly how the nitro group in GTN is converted into NO is still uncertain, although the general belief is that an enzyme is responsible. Introduction Th e nineteenth and twentieth centuries witnessed a Figure 1. Ascanio Sobrero. (Source: University of Torino surge in the number of new compounds made in the Archive) laboratory that were available for testing as possible drugs. Not only were the physical properties (colour, GTN was fi rst synthesised by an Italian, Ascanio So- crystal form, melting point and so on) of new com- brero (1812-1888) around 1847. (Figure 1). He was born pounds recorded, but the discoverer might do a few in the small town of Casale Monferrato in the Pied- simple tests to see whether the compound had any in- mont region of Italy and studied medicine at the near- teresting biological properties.
    [Show full text]
  • NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE Criteria for a Recommended Standard OCCUPATIONAL EXPOSURE to NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE
    CRITERIA FOR A RECOMMENDED STANDARD OCCUPATIONAL EXPOSURE TO NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE criteria for a recommended standard OCCUPATIONAL EXPOSURE TO NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Center for Disease Control National Institute for Occupational Safety and Health June 1978 For »ale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402 DISCLAIMER Mention of company name or products does not constitute endorsement by the National Institute for Occupational Safety and Health. DHEW (NIOSH) Publication No. 78-167 PREFACE The Occupational Safety and Health Act of 1970 emphasizes the need for standards to protect the health and provide for the safety of workers occupationally exposed to an ever-increasing number of potential hazards. The National Institute for Occupational Safety and Health (NIOSH) evaluates all available research data and criteria and recommends standards for occupational exposure. The Secretary of Labor will weigh these recommendations along with other considerations, such as feasibility and means of implementation, in promulgating regulatory standards. NIOSH will periodically review the recommended standards to ensure continuing protection of workers and will make successive reports as new research and epidemiologic studies are completed and as sampling and analytical methods are developed. The contributions to this document on nitroglycerin (NG) and ethylene glycol dinitrate (EGDN) by NIOSH staff, other Federal agencies or departments, the review consultants, the reviewers selected by the American Industrial Hygiene Association, and by Robert B. O ’Connor, M.D., NIOSH consultant in occupational medicine, are gratefully acknowledged. The views and conclusions expressed in this document, together with the recommendations for a standard, are those of NIOSH.
    [Show full text]
  • US5489610.Pdf
    |||||||| US00548961OA United States Patent 19 11 Patent Number: 5,489,610 Fung et al. 45) Date of Patent: 8 Feb. 6, 1996 54 SUSTAINED RELEASE ORGANIC NITRITE 58 Field of Search .................................... 514/506, 509, THERAPY 514/645, 740 75 Inventors: Ho-Leung Fung, Getzville; John A. 56) References Cited Bauer, Williamsville, both of N.Y. U.S. PATENT DOCUMENTS 73 Assignee: Research Foundation of the State 5,278,192 l/1994 Fung et al. .............................. 514f645 University of New York, Albany, N.Y. OTHER PUBLICATIONS * Notice: The portion of the term of this patent Derwent Abstracts 78–35053A, "Medicaments for Treating disclaimed.subsequent to Jan. 11, 2011, has been Cardiardiogenic Shock”, Fribolinis is et al. (1978). Patent Abstracts of Japan, vol. 12, No. 467, Dec. 7, 1988, 21 Appl. No.: 199,280 "Tape Preparation'. 22, PCT Filed: Jun. 30, 1993 Primary Examiner-Frederick Krass Attorney, Agent, or Firm-Kirschstein et al. 86 PCT No.: PCT/US93/06235 (57) ABSTRACT S371 Date: Mar. 1, 1994 A method of treating a patient suffering from a condition S 102(e) Date: Mar. 1, 1994 requiring vasodilator therapy, comprising long term, con 87 PCT Pub. No.: WO94/01103 tinuous adminstration of an organic nitrite to the patient in a dosage form capable of delivering a sufficient therapeutic PCT Pub. Date:Jan. 20, 1994 amount of nitrite to the bloodstream of the patient thereby providing effective vasodilator therapy for at least 24 hours Related U.S. Application Data without the development of tolerance in the patient. The a method of the invention is useful in treating conditions such 63 Continuation-in-part of Ser.
    [Show full text]
  • Cocaine/Heroin Induced Rhabdomyolysis and Ventricular Fibrillation B Mccann, R Hunter, J Mccann
    264 CASE REPORTS Emerg Med J: first published as 10.1136/emj.19.3.270 on 1 May 2002. Downloaded from Cocaine/heroin induced rhabdomyolysis and ventricular fibrillation B McCann, R Hunter, J McCann ............................................................................................................................. Emerg Med J 2002;19:264–265 PaO2: 24.3 kPa; base deficit: 18.0 mmol/l; lactate: 8.4 mmol/l. A case of cardiorespiratory arrest in a 28 year old Creatine phosphokinase: 90 500 IU/l (normal range 33–194). man after cocaine and heroin ingestion is described. The Urine: myoglobin: positive; cocaine metabolites: positive; arrest is attributed primarily to hyperkalaemia/ opioids: positive. rhabdomyolysis—a recognised consequence of each of Consequent upon his rhabdomyolysis he developed acute these drugs. The administration of naloxone may have renal failure requiring haemodialysis, disseminated intravas- been contributory. He developed acute renal failure, cular coagulopathy and right lower limb compartment disseminated intravascular coagulopathy with consequent syndrome requiring fasciotomy. Echocardiogram showed a lower limb compartment syndrome requiring fasciotomy. left ventricular ejection fraction of 53%. Respiratory function Ventricular fibrillation was identified at thoracotomy. remained stable. At day 10 (after tracheostomy) he had spon- taneous eye opening, flexed to pain and had no response to verbal commands. Brain stem reflexes were intact. Computed tomographic scan of his brain was normal. 28 year old man was brought to the emergency depart- The patient died two months later. Cause of death was ment after intravenous ingestion of cocaine and heroin. bronchopneumonia complicating multiorgan failure. AHe was noted to be pale, cyanosed, bradypnoeic (6/min), and hypotensive (70/40). DISCUSSION Initial treatment consisted of oxygen via a facemask, and 800 Rhabdomyolysis is a well documented complication of cocaine µg of naloxone intravenously.
    [Show full text]
  • Hazard Summary Identification Reason For
    Common Name: AMYL NITRITE CAS Number: 110-46-3 RTK Substance number: 0132 DOT Number: UN 1113 Date: March 1987 Revised: September 2000 ----------------------------------------------------------------------- ----------------------------------------------------------------------- HAZARD SUMMARY * Amyl Nitrite can affect you when breathed in and by * Exposure to hazardous substances should be routinely passing through your skin. evaluated. This may include collecting personal and area * Contact can irritate the skin and eyes and may cause air samples. You can obtain copies of sampling results blurred vision. from your employer. You have a legal right to this * Breathing Amyl Nitrite can irritate the nose and throat information under OSHA 1910.1020. causing coughing and wheezing. * If you think you are experiencing any work-related health * Exposure to Amyl Nitrite can cause nausea, vomiting, problems, see a doctor trained to recognize occupational weakness, confusion, restlessness and convulsions. diseases. Take this Fact Sheet with you. * High levels can interfere with the ability of the blood to carry Oxygen causing headache, fatigue, dizziness, and a WORKPLACE EXPOSURE LIMITS blue color to the skin and lips (methemoglobinemia). No occupational exposure limits have been established for Higher levels can cause trouble breathing, collapse and Amyl Nitrite. This does not mean that this substance is not even death. harmful. Safe work practices should always be followed. * Repeated exposure may damage the blood cells causing a low blood count (anemia). * It should be recognized that Amyl Nitrite can be absorbed * Amyl Nitrite is a HIGHLY FLAMMABLE and through your skin, thereby increasing your exposure. REACTIVE chemical and a DANGEROUS FIRE and EXPLOSION HAZARD. WAYS OF REDUCING EXPOSURE * Where possible, enclose operations and use local exhaust IDENTIFICATION ventilation at the site of chemical release.
    [Show full text]
  • Hazardous Waste List (California Code of Regulations, Title 22 Section 66261.126)
    Hazardous Waste List (California Code of Regulations, Title 22 Section 66261.126) Appendix X - List of Chemical Names and Common Names for Hazardous Wastes and Hazardous Materials (a) This subdivision sets forth a list of chemicals which create a presumption that a waste is a hazardous waste. If a waste consists of or contains a chemical listed in this subdivision, the waste is presumed to be a hazardous waste Environmental Regulations of CALIFORNIA unless it is determined that the waste is not a hazardous waste pursuant to the procedures set forth in section 66262.11. The hazardous characteristics which serve as a basis for listing the chemicals are indicated in the list as follows: (X) toxic (C) corrosive (I) ignitable (R) reactive * =Extremely Hazardous A chemical denoted with an asterisk is presumed to be an extremely hazardous waste unless it does not exhibit any of the criteria set forth in section 66261.110 and section 66261.113. Trademark chemical names are indicated by all capital letters. 1. Acetaldehyde (X,I) 2. Acetic acid (X,C,I) 3. Acetone, Propanone (I) 4. *Acetone cyanohydrin (X) 5. Acetonitrile (X,I) 6. *2-Acetylaminofluorene, 2-AAF (X) 7. Acetyl benzoyl peroxide (X,I,R) 8. *Acetyl chloride (X,C,R) 9. Acetyl peroxide (X,I,R) 10. Acridine (X) 11. *Acrolein, Aqualin (X,I) 12. *Acrylonitrile (X,I) 13. *Adiponitrile (X) 14. *Aldrin; 1,2,3,4,10,10-Hexachloro-1,4,4a,5,8,8a-hexahydro-1,4,5,8-endo-exodimethanonaphthlene (X) 15. *Alkyl aluminum chloride (C,I,R) 16. *Alkyl aluminum compounds (C,I,R) 17.
    [Show full text]
  • Amyl Nitrate Is Also Referred to As
    Amyl Nitrate Is Also Referred To As Vitreum Jared browsed her hoovers so downright that Shane disguisings very astringently. Treeless soand septennially ascitic Christof or misteach always recreate any unrestraints much and meteorologically. hogties his ranches. Exarate Micheal never overpeopled Initial epidemiologic studies indicated that gentle use of inhalant drugs such as amyl nitrite isobutyl nitrite IBN and butyl nitrite may raise a risk factor for acquired. Using amyl nitrate from. Users often also referred to amyl nitrite. What are Poppers Where they even Be Purchased and Dangers. Can nitrates be added to a sign schedule or allow scripting from sexual health practitioners? Clinical and nitrates. Using too much amyl nitrite may prefer a dangerous overdose If regular medicine does science seem fine be plenty as old after money have used it require a while check been your doctor to not pocket the dose on my own. The patient was maintained in the method is common are swallowed, that pushed underground into the fumes for example, dizziness and severity of aids in. Alkyl nitrates also refers to amyl is our patient had thrombocytopenia, with reference entry into phosgene and levels can potentially deadly substance choice for. Amyl nitrite Rx Medscape Reference. Burroughs wellcome and to as literature, but notthat of the manufacturing nitroglycerin or vitals and sometimes serious lung metabolism. Nitrite are two very similar to psychological withdrawal is not result in these products to dilate the rat by particular sections of subjects. The nitrate is to nitrates are referred to browse this? Diseases and contaminants: nitrate and drinking water or private wells.
    [Show full text]
  • Health Hazards of Nitrite Inhalants, 83
    Health Hazards of Nitrite Inhalants U.S. DEPARMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Health Hazards of Nitrite Inhalants Editors: Harry W. Haverkos, M.D. Divlsion of Clinical Research National Institute on Drug Abuse John A. Dougherty, Ph.D. Veterans Administration Medical Center Lexington, KY NIDA Research Monograph 83 1988 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5500 Fishers Lane Rockville, MD 20857 For Sale by the Superitendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. MARY L. JACOBSON Temple Universlty School of Medicine National Federation of Parents for Philadelphia, Pennsylvania Drug-Free Youth Omaha, Nebraska SYDNEY ARCHER, Ph.D. Rensselaer Polytechnic Institute Troy, New York REESE T. JONES, M.D. Langley Porter Neuropsychiatric lnstitute RICHARD E. BELLEVILLE, Ph.D. San Francisco, California NB Associates, Health Sciences RockviIle, Maryland DENISE KANDEL, Ph.D. KARST J. BESTEMAN College of Physicians and Surgeons of Alcohol and Drug Problems Association Columbia University of North America New York, New York Washington, D.C GILBERT J.
    [Show full text]
  • THE DIAGNOSIS and TREATMENT of CARDIAC PAIN. by Amyl Nitrite
    April, 1936 DIAGNOSIS AND TREATMENT OF CARDIAC PAIN 129 Postgrad Med J: first published as 10.1136/pgmj.12.126.129 on 1 April 1936. Downloaded from THE DIAGNOSIS AND TREATMENT OF CARDIAC PAIN. By GEOFFREY BOURNE, M.D., F.R.C.P. (Assistant Physician, Officer in charge Cardiology Dept., St. Bartholomew's Hospital; Physician, King George Hospital, Ilford.) The most necessary factor in treatment is accurate diagnosis and there is no subject where this is more true than in that of cardiac pain. The chief con- ditions in which cardiac pain occurs are, I. Coronary Thrombosis, 2. Angina of Effort, 3. Spasmodic Angina, and 4. Angina Innocens. I. CORONARY THROMBOSIS. Coronary thrombosis is now well recognized as a clinical entity, and its symptoms and signs are understandable in the light of the pathological changes Protected by copyright. which are found by post-mortem examination. Pathology and Symptoms. The sudden blocking of the artery produces an abrupt anaemia of a consider- able mass of living heart muscle. This produces pain. Certain changes take place in the infarcted area, necrosis, fibrosis, and to a certain extent recovery which occurs by virtue of the presence of some collateral circulation at the periphery of the infarct. As these changes proceed, the pain slowly dies down, and has generally completely disappeared by the end of the week. The amount of pain varies greatly from case to case, and in some cases is comparatively mild. The characteristics of the process are the sudden onset, the fact that the pain http://pmj.bmj.com/ is at its greatest at first, and that it slowly subsides during a period of days.
    [Show full text]